We could not find any results for:
Make sure your spelling is correct or try broadening your search.
RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem. RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem.
LOS ALTOS, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies based on a...
LOS ALTOS, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology...
LOS ALTOS, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology...
Phase III clinical trial is evaluating RenovoGem™ for the treatment of Locally Advanced Pancreatic Cancer UNMC opened enrollment of TIGeR-PaC in June 2024 and joins esteemed clinical sites...
Published data shows that chemotherapy delivered via TAMP™ with prior chemoradiation in Locally Advanced Pancreatic Cancer (LAPC) observed an Overall Survival (OS) of 27-months Targeted...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0206 | -2.01960784314 | 1.02 | 1.1 | 0.995 | 19642 | 1.02365094 | CS |
4 | -0.0906 | -8.3119266055 | 1.09 | 1.3 | 0.9499 | 51409 | 1.08654884 | CS |
12 | -0.2806 | -21.921875 | 1.28 | 1.31 | 0.93 | 34210 | 1.09701592 | CS |
26 | -0.1506 | -13.0956521739 | 1.15 | 1.48 | 0.93 | 37744 | 1.15339527 | CS |
52 | -0.1306 | -11.5575221239 | 1.13 | 2.35 | 0.5306 | 52013 | 1.31541478 | CS |
156 | -4.8006 | -82.7689655172 | 5.8 | 12.4999 | 0.5306 | 317183 | 6.37703879 | CS |
260 | -7.2506 | -87.8860606061 | 8.25 | 16.74 | 0.5306 | 405738 | 7.63980696 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions